The 6 most recent market catalysts affecting $BLRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026
BioLineRx and Hemispherian have announced the acceptance of two abstracts, including one oral presentation, for GLIX1 preclinical efficacy in orthotopic glioblastoma models at the …
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 55
Watching BioLineRx; Zacks Small-Cap Research Gives Stock $18 Price Valuation
The headline highlights a specific price target for BioLineRx (BLRX) from Zacks Small-Cap Research. This is a positive catalyst for BLRX, as a higher valuation from a reputable res…
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 92
BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate
BioLine Rx (BLRX) announced Q2 sales of $294,000, falling short of the $500,000 analyst consensus by a substantial 41.20%. This underperformance is further compounded by a 3.29% de…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 75
BioLineRx shares are trading lower after the company announced a $3.75 million offering of ADSs at $2.78 each.
This headline directly impacts BioLineRx (BLRX) as the company is issuing new American Depositary Shares (ADSs). A stock offering, especially at a price below the current market va…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs
BioLineRx is raising capital through a registered direct offering of ADSs and a concurrent private placement of warrants. This move is significant because it provides the company w…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 55
BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October
BioLineRx is announcing an upcoming presentation at a major medical conference in October 2026, detailing pre-clinical data on its GLIX1 compound. This data suggests a strong syner…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.